Cognitive Functioning in Adults With Somatic Diseases and General Population From a Biopsychosocial Perspective

Cognitive Functioning Profiles in Adults With Neurologically Recognized Aphasic Syndromes and General Population From a Biopsychosocial Perspective

The goal of this observational study is to investigate cognitive functioning profiles in adults with neurologically recognized aphasic syndromes and general population.

The study group consist of minimal 600 adults (over 18 y.o.) who will be examined by qualified diagnosticians. Participants will be evaluated with tasks related to the studied variables: memory, learning and language. Furthermore informations regarding past and present health condition will be collected from participants.

The main questions it aims to answer are:

1. What is the profile of memory and learning among polish adults?
2. Do gender and age moderates patterns of memory and learning functioning among polish adults?
3. What is a specific pattern of language functioning in adults with neurologically recognized aphasic syndromes?
4. Do gender moderates specific patterns of language functioning in adults with neurologically recognized aphasic syndromes?

Researchers will compare the following groups of adults:

1. general population/control group
2. with neurologically recognized aphasic syndromes
3. seniors (over 60 y.o.)

Study Overview

• Status: Recruiting
• Conditions: Aphasia; Neuropathology; Development, Human
• Intervention / Treatment: Diagnostic test: Psychological assessment

• Study Type: Observational
• Enrollment (Estimated): 600

Contacts and Locations

• Study Contact: Name: Rafał Nowicki, M.A.; Phone Number: +48509805591; Email: nowicki@pracowniatestow.pl

Study Locations

• Poland
  • Pomerania
    • Gdansk, Pomerania, Poland, 80-239
      • Recruiting
      • Laboratory of Psychological and Educational Tests
      • Contact: Rafał Nowicki, M.A.; Phone Number: +48509805591; Email: nowicki@pracowniatestow.pl
      • Sub-Investigator: Rafał Nowicki, M.A.
      • Sub-Investigator: Artur Sawicki, M.A.
      • Principal Investigator: Urszula Sajewicz-Radtke, Ph.D.
      • Principal Investigator: Bartosz M Radtke, Ph.D.
      • Principal Investigator: Ariadna Łada-Maśko, Ph.D.
      • Sub-Investigator: Beata Daniluk, Ph.D.
      • Sub-Investigator: Piotr Markiewicz, Ph.D.
      • Sub-Investigator: Paweł Jurek, Ph.D.
      • Sub-Investigator: Michał Olech, Ph.D.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: N/A

• Sampling Method: Non-Probability Sample

Study Population

Polish adults.

Description

Inclusion criteria for general population/control group:

• age from 18 to 60 y.o.

Inclusion criteria for neurologically recognized aphasic syndromes

• age above 18 y.o.
• neurologically recognized aphasic syndromes

Inclusion criteria for seniors:

• age above 60 y.o.

Exclusion criteria for general population/control group:

• age less then 18 y.o.
• neurologically recognized aphasic syndromes

Exclusion criteria for neurologically recognized aphasic syndromes

• age less then 18 y.o.
• no neurologically recognized aphasic syndromes

Exclusion criteria for seniors

• age less then 60 y.o.
• diseases of the nervous system, such as: stroke, craniocerebral trauma, neuroinfections, neurodegenerative diseases
• mental disorders such as depression, psychotic disorders, anxiety disorders, addictions

Study Plan

How is the study designed?

Number of groups / cohorts

3

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
General population/control group; Polish adults (age 18 to 60 y.o).	Diagnostic test: Psychological assessment; Psychological assessment of memory, learning and language
Neurologically recognized aphasic syndromes; Polish adults (age 18 to 60 y.o) with neurologically recognized aphasic syndromes.	Diagnostic test: Psychological assessment; Psychological assessment of memory, learning and language
Seniors (over 60 y.o); Polish adults (over 60 y.o.)	Diagnostic test: Psychological assessment; Psychological assessment of memory, learning and language

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Socio-demographic data	Author's survey of socio-demographic data, including: gender, month and year of birth, region of residence	July 3, 2023 until March 31, 2025
Memory and learning	Test of Memory and Learning (second edition). A standardized test measuring memory functioning and learning abilities. The test includes four basic factors (Verbal Memory, Nonverbal Memory, Complex Memory, and Delayed Recall) and five supplementary factors (Attention/Concentration, Sequential Memory, Free Recall, Associative Recall and Learning). The raw scores obtained in each tested subscale are converted into scores scaled based on age norms, ranging from 1 to 20, where a higher score means better functioning of the examined area, and a lower result means poorer functioning.	July 3, 2023 until March 31, 2025
Language	Boston Diagnostic Aphasia Examination-Third Edition. A spectrum of tools that helps to identify and distinguish among disorders of language function and neurologically recognized aphasic syndromes. The test have five functional subsections: 1) Conversational and Expository Speech, 2) Auditory Comprehension, 3) Oral Expression, 4) Reading and 5) Writing. The raw scores obtained in each tested subscale are converted into a percentile scale, ranging from 1 to 100, where a higher score means better functioning of the examined area, and a lower result means poorer functioning.	July 3, 2023 until March 31, 2025

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Health related data	Author's survey of health related data, including: hearing, eyesight, hypertension, atherosclerosis, previous heart attack, diabetes, endocrine diseases, respiratory system diseases, musculoskeletal system diseases, nervous system diseases, kidney diseases, sleep disorders, hospitalizations, procedures under general anesthesia, cancer, medications.	July 3, 2023 until March 31, 2025
Education data	Author's survey of education, including: years of education, level of education, occupation, level of education of the participant's parents.	July 3, 2023 until March 31, 2025
General mental state	Mini-Mental State Examination. A clinical scale used to examine disorders in a patient's cognitive functioning. The questionnaire consists a series of questions allowing the assessment of the following functions: 1) orientation in time and place, 2) attention/concentration, 3) short-term memory (recall), 4) language skills, 5) visual-spatial abilities, 6) ability to understand and follow the instructions. The maximum score that can be obtained on the test is 30 points. 27-30 is a correct result; 24-26 is a cognitive impairment without dementia; 19-23 mean mild dementia; 11-18 is a moderate degree dementia and 0-10 mean profound dementia.	July 3, 2023 until March 31, 2025

Collaborators and Investigators

• Sponsor: Bartosz M. Radtke
• Investigators: Principal Investigator: Ariadna Łada-Maśko, Ph.D., Laboratory of Psychological and Educational Tests; Study Director: Urszula Sajewicz-Radtke, Ph.D., Laboratory of Psychological and Educational Tests; Principal Investigator: Bartosz M Radtke, Ph.D., Laboratory of Psychological and Educational Tests

Study record dates

Study Major Dates

• Study Start (Actual): July 3, 2023
• Primary Completion (Estimated): March 1, 2025
• Study Completion (Estimated): December 1, 2025

Study Registration Dates

• First Submitted: April 10, 2024
• First Submitted That Met QC Criteria: April 10, 2024
• First Posted (Actual): April 15, 2024

Study Record Updates

• Last Update Posted (Actual): April 22, 2024
• Last Update Submitted That Met QC Criteria: April 19, 2024
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Keywords: memory; learning; language; adults; aphasia; seniors
• Additional Relevant MeSH Terms: Nervous System Diseases; Neurologic Manifestations; Neurobehavioral Manifestations; Language Disorders; Communication Disorders; Speech Disorders; Aphasia
• Other Study ID Numbers: 2024/PTPiP/1

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No